Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma.

Autor:	Omar A; Department of Gastroenterology, Faculty of Medicine, Cairo University, Cairo, Egypt., Kaseb A; Department of Gastrointestinal Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA., Elbaz T; Department of Gastroenterology, Faculty of Medicine, Cairo University, Cairo, Egypt., El-Kassas M; Department of Endemic Medicine, Faculty of Medicine, Helwan University, Cairo, Egypt., El Fouly A; Department of Endemic Medicine, Faculty of Medicine, Helwan University, Cairo, Egypt., Hanno AF; Department of Gastroenterology, Faculty of Medicine, Alexandria University, Alexandria, Egypt., El Dorry A; Department of Interventional Radiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Hosni A; Department of Interventional Radiology, Faculty of Medicine, Cairo University, Cairo, Egypt., Helmy A; Department of Surgery, National Liver Institute Menoufia University, Menoufia, Egypt., Saad AS; Department of Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Alolayan A; Department of Oncology, National Guard Hospital, Riyadh, Saudi Arabia., Eysa BE; Department of Gastroenterology, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt., Hamada E; Department of Oncology, Faculty of Medicine, Cairo University, Cairo, Egypt., Azim H; Department of Oncology, Faculty of Medicine, Cairo University, Cairo, Egypt., Khattab H; Department of Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt., Elghazaly H; Department of Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Tawfik H; Department of Oncology, Faculty of Medicine, Tanta University, Tanta Egypt., Ayoub H; Department of Gastroenterology, Military Medical Academy, Cairo, Egypt., Khaled H; Department of Oncology, Faculty of Medicine, Cairo University, Cairo, Egypt., Saadeldin I; Department of Oncology, Faculty of Medicine, Cairo University, Cairo, Egypt., Waked I; Department of Gastroenterology, Menoufia Liver Institute, Menoufia, Egypt., Barakat EMF; Department of Gastroenterology, Faculty of Medicine, Ain Shams University, Cairo, Egypt., El Meteini M; Department of Surgery, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Hamed Shaaban M; Department of Interventional Radiology, Faculty of Medicine, Cairo University, Cairo, Egypt., EzzElarab M; Department of Gastroenterology, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt., Fathy M; Department of Surgery, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Shaker M; Department of Interventional Radiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Sobhi M; Department of Interventional Radiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Shaker MK; Department of Gastroenterology, Faculty of Medicine, Ain Shams University, Cairo, Egypt., ElGharib M; Department of Interventional Radiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Abdullah M; Department of Oncology, Faculty of Medicine, Cairo University, Cairo, Egypt., Mokhtar M; Department of Oncology, Faculty of Medicine, Cairo University, Cairo, Egypt., Elshazli M; Department of Surgery, Faculty of Medicine, Cairo University, Cairo, Egypt., Heikal OMK; Department of Gastroenterology, Military Medical Academy, Cairo, Egypt., Hetta O; Department of Interventional Radiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt., ElWakil RM; Department of Gastroenterology, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Abdel Wahab S; Department of Interventional Radiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Eid SS; Department of Oncology, Faculty of Medicine, Assiut University, Assiut, Egypt., Rostom Y; Department of Oncology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Jazyk:	angličtina
Zdroj:	Journal of hepatocellular carcinoma [J Hepatocell Carcinoma] 2023 Sep 18; Vol. 10, pp. 1547-1571. Date of Electronic Publication: 2023 Sep 18 (Print Publication: 2023).
DOI:	10.2147/JHC.S404424
Abstrakt:	Globally, hepatocellular carcinoma (HCC) is the fourth most common cause of death from cancer. The prevalence of this pathology, which has been on the rise in the last 30 years, has been predicted to continue increasing. HCC is the most common cause of cancer-related morbidity and mortality in Egypt and is also the most common cancer in males. Chronic liver diseases, including chronic hepatitis C, which is a primary health concern in Egypt, are considered major risk factors for HCC. However, HCC surveillance is recommended for patients with chronic hepatitis B virus (HBV) and liver cirrhosis; those above 40 with HBV but without cirrhosis; individuals with hepatitis D co-infection or a family history of HCC; and Nonalcoholic fatty liver disease (NAFLD) patients exhibiting significant fibrosis or cirrhosis. Several international guidelines aid physicians in the management of HCC. However, the availability and cost of diagnostic modalities and treatment options vary from one country to another. Therefore, the current guidelines aim to standardize the management of HCC in Egypt. The recommendations presented in this report represent the current management strategy at HCC treatment centers in Egypt. Recommendations were developed by an expert panel consisting of hepatologists, oncologists, gastroenterologists, surgeons, pathologists, and radiologists working under the umbrella of the Egyptian Society of Liver Cancer. The recommendations, which are based on the currently available local diagnostic aids and treatments in the country, include recommendations for future prospects. Competing Interests: Dr Hamdy Azim reports grants, personal fees from Roche, grants from Astra Zenca, personal fees from Bayer, during the conduct of the study; grants, personal fees from Novartis, grants, personal fees from Pfizer, grants, personal fees from MSD, personal fees from BMS, personal fees from GSK, outside the submitted work. Prof. Dr. Imam Waked reports personal fees, Investigator Advisory Board Member from Astra Zeneca, personal fees from Hoffman La Roche, personal fees from Bayer, during the conduct of the study; Investigator from Abbvie, personal fees, Advisory Board from Eva Pharma, Investigator from Pfizer, other from Investigator, outside the submitted work. The authors report no other conflicts of interest in this work. (© 2023 Omar et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu